Day: 28. October 2016

Astellas acquires German Ganymed Pharmceuticals, an antibody specialist

Ganymed (CEO Dr. Özlem Türeci) is a biopharmaceutical company located in Mainz, Germany, which focuses on the development of antibodies against cancer. Under the contract, Astellas will pay EUR 422 million to acquire 100% of the equity in Ganymed. In addition, Ganymed’s shareholders will become eligible to receive up to EUR 860 million in further […]

Scroll to top